Abstract
Multiple myeloma (MM) remains an incurable malignancy despite the recent advancements in its treatment. The protective effects of the niche in which it develops has been well documented; however, little has been done to investigate the MM cell’s ability to ‘re-program’ cells within its environment to benefit disease progression. Here, we show that MM-derived macrophage migratory inhibitory factor (MIF) stimulates bone marrow stromal cells to produce the disease critical cytokines IL-6 and IL-8, prior to any cell-cell contact. Furthermore, we provide evidence that this IL-6/8 production is mediated by the transcription factor cMYC. Pharmacological inhibition of cMYC in vivo using JQ1 led to significantly decreased levels of serum IL-6—a highly positive prognostic marker in MM patients.
| Original language | English |
|---|---|
| Article number | 66 |
| Journal | Journal of Hematology & Oncology |
| Volume | 11 |
| DOIs | |
| Publication status | Published - 16 May 2018 |
Keywords
- Myeloma
- MIF
- cMYC
- BMSC
- StromalI
- L-6I
- L-8
- Bone marrow
Profiles
-
Kristian Bowles
- Norwich Medical School - Dean of Norwich Medical School
- Metabolic Health - Member
- Cancer Studies - Member
Person: Honorary, Research Group Member, Research Centre Member
-
Stuart Rushworth
- Norwich Medical School - Professor
- Metabolic Health - Director
- Cancer Studies - Member
Person: Research Group Member, Academic, Teaching and Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver